HIMSS Analytics Announces Siemens as Certified Educator of the DELTA-Powered Analytics Assessment

CHICAGO (June 23, 2014) – HIMSS Analytics today named Siemens Healthcare a Certified Educator of the DELTA PoweredTM Analytics Assessment.

The first healthcare industry benchmark designed to measure and score analytical maturity, the DELTA Powered Analytics Assessment, and its associated business intelligence (BI) maturity model, gives healthcare provider organizations the ability to measure the strength of their analytics program, benchmark relative to their peers, and provides insight into where an organization should focus to advance analytics capabilities and maturity.

As healthcare providers rapidly accumulate massive amounts of data and shift to valued-based and accountable care models it has created a need to leverage data to gain valuable clinical and business insights. “This is about more than simply collecting data,” said Blain Newton, Sr. VP and COO, HIMSS Analytics. “It is about maximizing how that data is used. Healthcare providers must now shift their attention to managing and maturing their analytic capabilities.  The DELTA Powered Analytics Assessment helps them to focus their efforts on the areas that will produce the most benefit.” 

“Through this certification and our recently launched Business Intelligence Advantage Services, we’re able to help our clients more effectively leverage data to bring their organizations to the next level of analytics maturity” said Mark Costanza, Senior Director of Strategic Consulting, Siemens Healthcare.  “Most healthcare provider organizations are struggling to formulate a strong long-term BI strategy, and Siemens is focused on providing the tools and expertise to help them succeed during this dynamic period in healthcare.”

Organizations achieving HIMSS Analytics Certified Educator status must pass an annual certification exam and commit to an annual educator program. This ensures they stay current with trends within the assessment, and are equipped with the necessary knowledge to help their clients advance through the various stages.

For more information on the DELTA Powered Analytics Assessment, visit www.himssanalytics.org/delta.

About HIMSS Analytics 
HIMSS Analytics is a wholly owned not-for-profit subsidiary of the Healthcare Information and Management Systems Society. The company collects and analyzes healthcare data related to IT processes and environments, products, IS department composition and costs, IS department management metrics, healthcare trends and purchase-related decisions. HIMSS Analytics delivers high quality data and analytical expertise to healthcare delivery organizations, healthcare IT companies, state governments, financial companies, pharmaceutical companies, and consulting firms. Visit http://www.himssanalytics.org/about/ for more information.

About Siemens Healthcare
The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 52,000 employees worldwide and operates around the world. In fiscal year 2013 (to September 30), the Sector posted revenue of 13.6 billion euros and profit of 2.0 billion euros. For further information please visit: www.siemens.com/healthcare.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.